VEGFA and cancer: Although VEGF-induced angiogenesis plays a pivotal role in the pathogenesis of RA (Fig. 1), the anti-VEGF agents that are currently used to treat cancer patients have serious side effects, especially grade 2–3 hypertension, which may limit the use of these agents in RA patients [10–13].